---
title: "Weekly Recap | ARCT.US +63.43%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296674467.md"
description: "Arcturus Therapeutics (ARCT) staged an explosive rally this week, surging 63.43% to close at $13.45 — a near one-year high. The S&P 500 shed 1.43% over the same stretch, leaving the stock ahead of the benchmark by roughly 64.86 percentage points."
datetime: "2026-08-22T06:58:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296674467.md)
  - [en](https://longbridge.com/en/news/296674467.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296674467.md)
generator: "portal-rs"
---

# Weekly Recap | ARCT.US +63.43%, most brokers rate it buy

## The Week

Arcturus Therapeutics (ARCT) staged an explosive rally this week, surging 63.43% to close at $13.45 — a near one-year high. The S&P 500 shed 1.43% over the same stretch, leaving the stock ahead of the benchmark by roughly 64.86 percentage points.

The week unfolded as an accelerating breakout. Monday and Tuesday saw quiet consolidation around $8 on thin volume. The move kicked off on Wednesday, with the stock jumping 25.2% to $10.28 on a massive 5.63m shares traded. The rally continued through Thursday and Friday, with the stock hitting an intraday high of $13.50 before settling at $13.45. Weekly amplitude reached 67.56%.

## Key Events

Broader biotech sentiment ran hot this week, and while Arcturus itself had no direct announcements, sector-wide optimism provided a strong tailwind.

On Wednesday, Arcturus appeared in multiple pre-market healthcare stock movers lists, and trading activity picked up sharply. Thursday brought the week’s loudest catalyst: Elon Musk called mRNA technology a ‘tremendous promise,’ and Moderna surged 177% on a cancer vaccine breakthrough. The endorsement lit a fire under the entire mRNA platform, and Arcturus — as a key player in the space — rallied hard into Friday’s close.

## Analyst Ratings

Thirteen brokers cover Arcturus, with 9 rating it buy, 1 overweight, and 3 hold. None rate it underweight or sell. The consensus recommendation is ‘buy’, and the consensus target sits at $20.20 — roughly 50.2% above the latest close of $13.45.

The range of individual targets is wide, spanning $8 to $40, reflecting sharply divergent views on the pipeline’s potential. Within the biotechnology industry, Arcturus ranks 85th out of 505 covered names.

## The Week Ahead

A cluster of US housing data lands on Tuesday, 25 August — FHFA and Case Shiller home price indices, alongside new home sales and consumer confidence figures. The consensus for consumer confidence is 90.1, down slightly from the prior 90.8.

With mRNA sentiment now firmly in the spotlight, the market will be watching for any pipeline updates from Arcturus and whether the sector’s momentum can hold.

## In Short

This week’s move in Arcturus was sentiment-driven rather than company-specific. The broker consensus leans clearly positive, with a consensus target well above the spot price, though the wide target range signals real uncertainty.

The latest session’s fund-flow data shows small-lot money as a net seller, while large and medium-sized money were more constructive. The question now is whether the mRNA buzz can translate into sustained interest — and whether Arcturus’s own pipeline can deliver the fundamentals to back it up.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)

## Related News & Research

- [Arcturus Therapeutics to Present ARCT-810 Data on OTC Deficiency at 2026 Symposium](https://longbridge.com/en/news/296895406.md)
- [Amova Asset Management Americas Inc. Grows Stock Holdings in Arcturus Therapeutics Holdings Inc. $ARCT](https://longbridge.com/en/news/293301940.md)
- [Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline](https://longbridge.com/en/news/295596260.md)
- [Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline](https://longbridge.com/en/news/285624062.md)
- [Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies](https://longbridge.com/en/news/288834555.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**